Despite the development of standard therapies, including surgery, radiotherapy and
chemotherapy, survival rates for head and neck squamous cell carcinoma (HNSCC) have …

Head and neck squamous cell carcinoma (HNSCC) of multi-factorial etiopathogenesis is
rising worldwide. Treatment-associated toxicity problems and treatment failure in advanced …

Opinion statement Worldwide more than a half million people develop Head and Neck
cancer annually. Despite a significant decrease in smoking, about 40,000 new patients are …

Head and neck cancer is a challenging disease that is expected to account for greater than
500,000 new cases worldwide in 2008. Toxicity has impeded advances in chemotherapy …

Simple Summary Next-generation sequencing of head and neck squamous cell carcinoma
has revealed multiple new gene mutations, while simultaneously confirming the role of …

Treatment of squamous cell carcinoma of the head and neck (SCCHN) has evolved greatly
in the last two decades, owing to the integration of chemotherapy, advances in …

Despite advances in multimodality therapies for the treatment of squamous cell carcinoma of
the head and neck (SCCHN), survival rates, functional outcomes and toxicities of therapy …

Despite progress in the therapeutic management of patients with squamous cell carcinoma
of the head and neck (SCCHN), the mortality rate of patients presenting with advanced …

In recent years, advances in drug therapy for head and neck squamous cell carcinoma
(HNSCC) have progressed rapidly. In addition to cytotoxic anti-cancer agents such as …

Targeted therapies have made their way into clinical practice during the past decade. They
have caused a major impact on the survival of cancer patients in many areas of clinical …